AnalystsMaury Raycroft
Maury Raycroft's Stock Forecasts

Sectors:
Industries:
Analyst Ranking
Bottom 8%
#4487 out of 4862 analysts
Average Return
-26.65%
Win Rate
16%7 out of 44
Risk vs Reward
Poor
Good

Maury Raycroft's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Reata Pharmaceuticals IncRETA
+198.41%$28.93$86.33
2017-08-29 -
2018-08-30
Strong Buy
Arrowhead Pharmaceuticals IncARWR
+157.02%$6.91$17.76
2018-03-26 -
2019-03-27
Strong Buy
Dianthus Therapeutics IncDNTH
+99.13%$11.50$22.90
2023-12-25 -
2024-12-24
Strong Buy
Tyra Biosciences IncTYRA
+88.64%$15.40$29.05
2021-10-10 -
2021-11-08
Strong Buy
Biocryst Pharmaceuticals IncBCRX
+54.64%$4.96$7.67
2017-09-05 -
2018-09-06
Strong Buy

Maury Raycroft Analyst Color

Get additional color on Maury Raycroft's coverage of popular stocks

Maury Raycroft's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Corbus Pharmaceuticals Holdings IncCRBP
2Strong Buy$53.00+741.27%Maintains
a month ago
Chimerix IncCMRX
2Hold$8.50-0.47%Downgrades
2 months ago
Compass Therapeutics IncCMPX
2Strong Buy$8.00+349.44%Maintains
2 months ago
Sangamo Therapeutics IncSGMO
1Strong Buy$3.00+307.61%Maintains
4 months ago
Mereo Biopharma Group PLCMREO
1Strong Buy$7.00+200.43%Initiates Coverage On
5 months ago
Erasca IncERAS
1Strong Buy$6.00+383.87%Initiates Coverage On
5 months ago
Inozyme Pharma IncINZY
1Strong Buy$17.00+1,636.47%Assumes
8 months ago
Tango Therapeutics IncTNGX
1Strong Buy$19.00+1,276.81%Initiates Coverage On
9 months ago
Calliditas Therapeutics AbCALT
2Hold$39.00-2.50%Downgrades
a year ago
Prime Medicine IncPRME
1Strong Buy$15.00+979.14%Assumes
a year ago
Dianthus Therapeutics IncDNTH
2Strong Buy$39.00N/AMaintains
a year ago
Cue Biopharma IncCUE
1Strong Buy$6.00N/AInitiates Coverage On
a year ago
Metagenomi IncMGX
1Strong Buy$23.00N/AInitiates Coverage On
a year ago
Tempest Therapeutics IncTPST
1Strong Buy$15.00N/AInitiates Coverage On
a year ago
Mirati Therapeutics IncMRTX
2Hold$58.00N/ADowngrades
2 years ago
Biocryst Pharmaceuticals IncBCRX
3Strong Buy$11.00N/AUpgrades
2 years ago
Reata Pharmaceuticals IncRETA
2Hold$172.50N/ADowngrades
2 years ago
Spectrum Pharmaceuticals IncSPPI
1Hold$1.50N/ADowngrades
2 years ago
Allakos IncALLK
2Strong Buy$9.00N/AUpgrades
2 years ago
Vera Therapeutics IncVERA
2Hold$6.00N/ADowngrades
2 years ago
Arrowhead Pharmaceuticals IncARWR
2Strong Buy$75.00N/AMaintains
2 years ago
Imago Biosciences IncIMGO
2Hold$36.00N/ADowngrades
2 years ago
Alnylam Pharmaceuticals IncALNY
1Strong Buy$232.00N/AMaintains
3 years ago
Rezolute IncRZLT
1Strong Buy$11.00N/AInitiates Coverage On
3 years ago
Forma Therapeutics Holdings IncFMTX
1Hold$20.00N/ADowngrades
3 years ago
Sierra Oncology IncSRRA
1Hold$55.00N/ADowngrades
3 years ago
Tyra Biosciences IncTYRA
3Strong Buy$27.00N/AUpgrades
3 years ago
Beyondspring IncBYSI
2Hold$5.00N/ADowngrades
3 years ago
Ayala Pharmaceuticals IncAYLA
1Strong Buy$17.00N/AUpgrades
3 years ago
Theseus Pharmaceuticals IncTHRX
1Strong Buy$23.00N/AInitiates Coverage On
3 years ago
Celcuity IncCELC
1Strong Buy$48.00N/AInitiates Coverage On
4 years ago
Aslan Pharmaceuticals LtdASLN
1Strong Buy$320.00N/AInitiates Coverage On
4 years ago
Valneva SeVALN
1Strong Buy$36.00N/AInitiates Coverage On
4 years ago
Solid Biosciences IncSLDB
1Strong Buy$105.00N/AInitiates Coverage On
4 years ago
Crispr Therapeutics AgCRSP
1Strong Buy$172.00N/AUpgrades
4 years ago
Checkmate Pharmaceuticals IncCMPI
1Strong Buy$22.00N/AInitiates Coverage On
5 years ago
Black Diamond Therapeutics IncBDTX
1Strong Buy$47.00N/AInitiates Coverage On
5 years ago
Affimed NvAFMD
5Strong Buy$40.00N/AUpgrades
7 years ago
Kezar Life Sciences IncKZR
1Strong Buy$230.00N/AInitiates Coverage On
7 years ago
Intellia Therapeutics IncNTLA
1Strong Buy$42.00N/AMaintains
7 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.